Post-Exposure Prophylaxis in Health Care Workers (PEP)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Objective: The objective of this study is to determine the safety and tolerability of Post-exposure Prophylaxis (PEP) with a regimen of Truvada + Kaletra among health care workers (HCWs) at Henry Ford Hospital.
Hypothesis: Raltegravir is safe and better tolerated compared with Kaletra, each in combination with Truvada, as assessed by review of completion rates of PEP and also review of completed safety data.
| Condition | Intervention | Phase |
|---|---|---|
|
Human Immunodeficiency Virus |
Drug: emtricitabine/tenofovir disoproxil fumarate |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Prospective, Randomized, Open Label Study to Evaluate the Safety and Tolerability of Raltegravir + Truvada Versus Kaletra + Truvada, for Post-exposure Prophylaxis in Health Care Workers |
- Evidence of toxicity [ Time Frame: Variables to be measured within 6 weeks between groups. ] [ Designated as safety issue: Yes ]The main outcomes of toxicity will be compared between the two groups using ANCOVA models in order to control for demographic and clinical variables.
- Evidence of virus transfer [ Time Frame: HIV ELISA variables measured within 24 weeks between groups ] [ Designated as safety issue: Yes ]The presence of virus transfer will be compred between the two groups using ANCOVA models in order to control for demographic and clinical variables.
| Enrollment: | 16 |
| Study Start Date: | February 2011 |
| Study Completion Date: | May 2013 |
| Primary Completion Date: | May 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Kaletra
Arm 1: Kaletra two tabs twice a day + Truvada one pill once a day.
|
Drug: emtricitabine/tenofovir disoproxil fumarate
Each health care worker will receive one of the Treatment Arms for 28 days.
Other Names:
|
|
Active Comparator: Raltegravir
Arm 2: Raltegravir 400 mg, one pill twice a day + Truvada one pill once a day.
|
Drug: emtricitabine/tenofovir disoproxil fumarate
Each health care worker will receive one of the Treatment Arms for 28 days.
Other Names:
|
Detailed Description:
Health Care Workers that have occupational exposure to blood are at risk for HIV infection. Prevention of blood exposure, through safer practices, barrier precautions, safer needle devices, and other innovations, is the best way to prevent infection with HIV and other bloodborne pathogens.
Though these strategies have been successful in reducing the frequency of blood exposure and needlestick injuries in the past decade, the hazard has not been eliminated. As of December 2001, the CDC had received voluntary reports of 57 documented cases of HIV seroconversion temporally associated with occupational exposure to HIV among U.S. health care personnel. An additional 138 infections among health care personnel were considered possible cases of occupational transmission. Because there is no cure or effective vaccine for HIV, optimal post exposure care, including the administration of antiretroviral drugs to prevent HIV infection, remains a high priority in protecting health care workers.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Adult (at least 18 years of age)employees of HFH
- History of occupational exposure to bodily fluids
- Negative HIV test
- The ability to understand a written informed consent form, which must be obtained prior to initiation of any study procedures
Exclusion Criteria:
- Positive pregnancy test
- Females who are breastfeeding
- History of renal disease
- Contraindication for treating patient with components of PEP regimen
- Greater than one dose of PEP medication for this exposure event
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT01234116
| United States, Michigan | |
| Henry Ford Hospital | |
| Detroit, Michigan, United States, 48202 | |
| Principal Investigator: | Indira Brar, M.D. | Henry Ford Health System |
More Information
No publications provided
| Responsible Party: | Indira Brar, MD, Senior Staff Physician Infectious Disease, Henry Ford Health System |
| ClinicalTrials.gov Identifier: | NCT01234116 History of Changes |
| Other Study ID Numbers: | PEP Study, 37384 |
| Study First Received: | November 2, 2010 |
| Last Updated: | September 26, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Henry Ford Health System:
|
Post exposure prophylaxis Health Care Workers |
Additional relevant MeSH terms:
|
Acquired Immunodeficiency Syndrome HIV Infections Immune System Diseases Immunologic Deficiency Syndromes Lentivirus Infections RNA Virus Infections Retroviridae Infections Sexually Transmitted Diseases Sexually Transmitted Diseases, Viral Slow Virus Diseases Virus Diseases Tenofovir |
Tenofovir disoproxil Anti-HIV Agents Anti-Infective Agents Anti-Retroviral Agents Antiviral Agents Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Nucleic Acid Synthesis Inhibitors Pharmacologic Actions Reverse Transcriptase Inhibitors Therapeutic Uses |
ClinicalTrials.gov processed this record on March 01, 2015